Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
85 hedge funds and large institutions have $362M invested in Chinook Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 40 increasing their positions, 21 reducing their positions, and 11 closing their positions.
963% more call options, than puts
Call options by funds: $170K | Put options by funds: $16K
90% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 21
3% less capital invested
Capital invested by funds: $372M → $362M (-$9.95M)
4% less funds holding
Funds holding: 89 → 85 (-4)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$10.8M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$7.53M |
| 3 |
State Street
Boston,
Massachusetts
|
+$6.03M |
| 4 |
Millennium Management
New York
|
+$4.65M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$13.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.56M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$3.76M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$1.65M |
| 5 |
Renaissance Technologies
New York
|
-$1.49M |
KDNY Hedge Fund Activity: Q3 2021 in Review
85 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2021, worth a combined $362M — down 2.7% from $372M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of KDNY and 8 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 40 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $10.8M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $13.2M sold.
- 85 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2021, down from 89 in Q2 2021.
- Funds reported $362M of Chinook Therapeutics, Inc. Common Stock stock for Q3 2021, down 2.7% quarter-over-quarter.
- 8 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2021 and 11 closed out, a net change of -3 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q3 2021 was Baker Bros. Advisors, an estimated $10.8M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2021 was EcoR1 Capital, an estimated $13.2M sold.
Based on aggregated 13F filings for Q3 2021.